染色体1家族阿尔茨海默氏病基因候选基因
E Levy-Lahad1, W Wasco, P Poorkaj
1Geriatric Research Education, and Clinical Center (182B), Veterans Affairs Medical Center, Seattle, WA 98108, USA.
Science (New York, N.Y.)
|August 18, 1995
概括
研究人员在第1染色体上发现了一种新的阿尔茨海默病 (AD) 基因STM2. 在AD家族中发现了STM2的突变 (N141l),支持其在疾病中的作用.
科学领域:
- 神经遗传学 神经遗传学
- 分子生物学分子生物学
- 人类遗传学 人类遗传学
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,具有复杂的遗传基础.
- 之前的研究已经确定了14号染色体上的AD易感点,与S182基因有关.
- 染色体1AD位点的遗传基础需要进一步研究.
研究的目的:
- 为了识别和表征与染色体1相关的候选基因,阿尔茨海默氏病 (AD) 位点.
- 调查突变在确定候选基因中的潜在致病作用.
主要方法:
- 对1号染色体AD位点进行定位候选基因分析.
- 候选基因之间的氨基酸序列同质性分析.
- 在伏尔加德语AD族的受影响个体中进行突变查.
- 跨物种突变地点的保护分析.
主要成果:
- 在染色体1上发现了一个候选基因STM2.
- 在STM2中,氨基酸序列与之前鉴定的染色体14AD基因S182.2.具有显著的同质性.
- 在沃尔加德国血统的阿尔茨海默病患者中,在STM2中检测到一种特定的点突变 (N141l).
- N141l突变部位在人类的S182和它的小鼠同类物体中都在进化过程中得到保护.
结论:
- 鉴定STM2作为染色体1AD位置的候选基因具有重要意义.
- STM2和S182之间的同质性,以及共同的突变模式,加强了与AD的遗传联系.
- 在两个非常相似的基因中存在误解突变,强烈支持STM2和S182突变在阿尔茨海默病中具有病原性.
更多相关视频
07:26High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
Published on: July 18, 2017
04:41Mapping Alzheimer's Disease Variants to Their Target Genes Using Computational Analysis of Chromatin Configuration
Published on: January 9, 2020
相关概念视频
01:11Genetic Lingo
Overview
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...